<?xml version="1.0" encoding="UTF-8"?>
<p>Renin-angiotensin-aldosterone system (RAAS) inhibitors, such as ACE inhibitors [ACE-i, e.g., captopril (21)] and angiotensin receptor blockers [ARB, e.g., losartan (22)], are commonly used in clinics to treat hypertension and cardiovascular/renal diseases.
 <xref rid="B132" ref-type="bibr">
  <sup>132</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B133" ref-type="bibr">
  <sup>133</sup>
 </xref> Recently, some researchers have debated over the administration of these drugs to patients with known or suspected COVID-19.
 <xref rid="B133" ref-type="bibr">
  <sup>133</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B134" ref-type="bibr">
  <sup>134</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B135" ref-type="bibr">
  <sup>135</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B136" ref-type="bibr">
  <sup>136</sup>
 </xref> The main reason for this discussion is that RAAS inhibitors may induce ACE2 expression, which, in theory, could increase the severity of the infection.
 <xref rid="B133" ref-type="bibr">
  <sup>133</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B136" ref-type="bibr">
  <sup>136</sup>
 </xref> Nonetheless, evidence suggests that these drugs may protect patients from lung injury by suppressing angiotensin II signaling mediated by angiotensin receptor 1 (AT1R).
 <xref rid="B135" ref-type="bibr">
  <sup>135</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B136" ref-type="bibr">
  <sup>136</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B137" ref-type="bibr">
  <sup>137</sup>
 </xref> Further investigation is still required to determine whether ACE-i and ARB have a beneficial or deleterious role in COVID-19 treatment.
 <xref rid="B134" ref-type="bibr">
  <sup>134</sup>
 </xref>
</p>
